We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+57.75%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$4.48B
AUM Growth
+$1.48B
Cap. Flow
+$437M
Cap. Flow %
9.75%
Top 10 Hldgs %
48.38%
Holding
120
New
23
Increased
28
Reduced
22
Closed
19

Top Buys

Rank Stock Value
1
CRGX
CARGO Therapeutics
CRGX
+$58.3M
2
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$55.9M
3
AXSM icon
Axsome Therapeutics
AXSM
+$37.2M
4
SYRE icon
Spyre Therapeutics
SYRE
+$34.8M
5
ABBV icon
AbbVie
ABBV
+$34.7M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$74M
2
IMVT icon
Immunovant
IMVT
+$54.7M
3
ROIV icon
Roivant Sciences
ROIV
+$44.6M
4
HRMY icon
Harmony Biosciences
HRMY
+$32.6M
5
RLAY icon
Relay Therapeutics
RLAY
+$16.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.85%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TYRA icon
76
Tyra Biosciences
TYRA
$1.81B
$4.99M 0.11%
360,000
– –
MLTX icon
77
MoonLake Immunotherapeutics
MLTX
$1.58B
$4.98M 0.11%
+82,398
New +$4.25M
NVAX icon
78
PUT
Novavax
NVAX
$1.2B
$4.75M 0.11%
1,400,000
+100,000
+8% +$612K
NBTX
79
Nanobiotix
NBTX
$1.88B
$4.04M 0.09%
555,066
– –
VERU icon
80
Veru
VERU
$35.2M
$4.02M 0.09%
558,470
+449,482
+412% +$3.99M
TVTX icon
81
Travere Therapeutics
TVTX
$5.13B
$3.6M 0.08%
400,000
– –
NVNO
82
enVVeno Medical
NVNO
$6.94M
$3.2M 0.07%
17,809
-4,523
-20% -$720K
ACAD icon
83
Acadia Pharmaceuticals
ACAD
$4.46B
$3.16M 0.07%
+101,000
New +$2.41M
XFOR icon
84
X4 Pharmaceuticals
XFOR
$372M
$2.97M 0.07%
118,182
– –
FBRX icon
85
Forte Biosciences
FBRX
$1.57B
$2.68M 0.06%
130,614
– –
CYTK icon
86
Cytokinetics
CYTK
$10.7B
$2.53M 0.06%
+30,317
New +$1.1M
KRON
87
DELISTED
Kronos Bio
KRON
$2.19M 0.05%
1,752,745
– –
ESTA icon
88
Establishment Labs
ESTA
$2.68B
$2.13M 0.05%
82,299
-195,384
-70% -$5.72M
CMAX
89
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$1.83M 0.04%
122,643
-4,809
-4% -$200K
MORF
90
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$1.65M 0.04%
+56,980
New +$1.36M
XBI icon
91
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.97B
$1.28M 0.03%
+1,900,000
New +$141M
AMAM
92
DELISTED
Ambrx Biopharma Inc
AMAM
$1.12M 0.03%
+78,811
New +$896K
OMIC
93
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$979K 0.02%
70,896
-7,878
-10% -$93.2K
VBIV
94
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$815K 0.02%
1,381,355
– –
APLT
95
CALL
DELISTED
Applied Therapeutics
APLT
$500K 0.01%
+500,000
New +$1.24M
CYPH
96
Cypherpunk Technologies Inc
CYPH
$63.1M
$186K ﹤0.01%
44,971
– –
BCAB icon
97
BioAtla
BCAB
$5.49M
$180K ﹤0.01%
+1,460
New +$127K
RVMDW icon
98
Revolution Medicines Inc Warrant
RVMDW
$92.6M
$82.5K ﹤0.01%
+250,000
New +$112K
EYPT icon
99
PUT
EyePoint Inc
EYPT
$988M
$37.5K ﹤0.01%
750,000
– –
SRZNW icon
100
Surrozen Inc Warrant
SRZNW
$36.6K
$3.33K ﹤0.01%
166,666
– –
1 2 3
4
5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q4 2023 Portfolio in Review

As of Q4 2023, Perceptive Advisors held 120 positions worth $4.48B, up 49% from $3B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Perceptive Advisors deployed $437M of net new capital in Q4 2023, opening 23 new positions and adding to 28 existing holdings. Its largest new stake was CARGO Therapeutics: 3,436,600 shares worth $79.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Immunovant, an estimated $54.7M trimmed.

  • Perceptive Advisors's largest Q4 2023 buy was CARGO Therapeutics: 3,436,600 shares worth $79.6M.
  • Perceptive Advisors added most to Rhythm Pharmaceuticals in Q4 2023, an estimated $55.9M increase.
  • Perceptive Advisors's biggest Q4 2023 reduction was Immunovant, cutting an estimated $54.7M.
  • Perceptive Advisors fully exited argenx in Q4 2023, selling an estimated $74M.
  • Perceptive Advisors's ten largest holdings make up 48% of its $4.48B portfolio in Q4 2023.
  • Perceptive Advisors opened 23 new positions and closed 19 in Q4 2023.
  • Perceptive Advisors's portfolio value rose 49% quarter-over-quarter to $4.48B.

Based on Perceptive Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.